Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Transcription Regulation of AgRP and POMC Genes

• Published in: Current issues in molecular biology 2024-07, Vol.46 (7), p.7505-7515
• Main Authors: Kim, Dong Hee, Lee, Min Jin, Kang, Dasol, Khang, Ah Reum, Bae, Ji Hyun, Kim, Joo Yeon, Kim, Su Hyun, Kang, Yang Ho, Yi, Dongwon
• Format: Article
• Language: English
• Subjects: energy homeostasis; hypothalamus; SGLT2 inhibitors
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb46070445

Sodium-glucose cotransporter 2 (SGLT2) inhibitors regulate plasma glucose levels in patients with type 2 diabetes mellitus (T2DM) by inhibiting renal glucose reabsorption. This study investigated the impact of empagliflozin (EMPA), an SGLT2 inhibitor, on hypothalamic energy regulation. To directly investigate the role of SGLT2 inhibitors in the hypothalamus, we administered EMPA through intracerebroventricular (i.c.v.) injections into the murine ventricles. After dental cementing the i.c.v. cannula onto the skull, the mice were given 5 days to recover before receiving vehicle or EMPA (50 nM/2 μL) injections. In a high-fat diet (HFD)-induced obesity model, we determined the gene expression levels of agouti-related peptide ( ) and pro-opiomelanocortin ( ) in the hypothalamus. Additionally, we assessed FoxO1 expression, which regulates and gene transcription in hypothalamic cell lines. We found that EMPA directly influenced the expression of endogenous mRNA of POMC and AgRP, which are critical for energy homeostasis, and modulated their transcription in high-fat diet-induced obese mice. Additionally, EMPA affected the expression of FoxO1, a key transcriptional regulator of glucose homeostasis, thereby regulating the transcriptional activity of and . These results indicate that EMPA significantly influences hypothalamic energy homeostasis, highlighting its potential as a regulator in obesity and T2DM management.